clinical validation to evaluate efficacy and safety of unani pharmacopeial formulation -Qurs -e-dawa-ul-shifa in zightuddam qawi(hypertension)
- Conditions
- Health Condition 1: I10- Essential (primary) hypertension
- Registration Number
- CTRI/2021/04/032863
- Lead Sponsor
- CCRUM
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 0
Following are inclusion criteria:
1 Subjects of either sex in the age group of 18-65 years.
2 Subjects of primary hypertension
3 Subjects of Grade- 1 Hypertension with Systolic BP [130–139]/ Diastolic BP [80–89]
4 Presence of any of the following symptoms and signs:
1 Suda(Headache)
2 Duwar(Vertigo)
3 Khafaqan(Palpitation)
4 Kasal (Laziness)
5 Takan(Fatigue)
•Waj-us-sadr(Chest pain)
•Kasrat-e-baul(Polyurea)
•NabzMumtali (Pulsusplenus)
Patients will be excluded who have any or more of the following conditions:
1.Pregnant and lactating women
2.Chronicity of disease more than 10 years
3.Subjects with SBP =140 mmHg and Diastolic BP >90 mmHg
4.Subjects with Secondary Hypertension
5.Subjects taking any other medication affecting blood pressure like NSAIDs and OCPs in females
6.Obese subjects – BMI >30
7.Systemic diseases requiring long term-treatment, e.g., DM-II, Malignancy, Epilepsy, cardiac and kidney diseases.
8.Subjects with Sinus Bradycardia, i.e., pulse rate less than 60/min
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Reduction in systolic and diastolic Blood pressureTimepoint: baseline,day 14,day 28,day 42,day 56,day 70,day 84
- Secondary Outcome Measures
Name Time Method reduction in symptomsTimepoint: reduction in symptoms in 12 weeks